| Identification | Back Directory | [Name]
Carbamic acid, N-ethyl-N-methyl-, 4-[7-[[(ethylmethylamino)carbonyl]oxy]-5-hydroxy-4-oxo-4H-1-benzopyran-2-yl]phenyl ester | [CAS]
2242792-25-0 | [Synonyms]
AChE-IN-15
Carbamic acid, N-ethyl-N-methyl-, 4-[7-[[(ethylmethylamino)carbonyl]oxy]-5-hydroxy-4-oxo-4H-1-benzopyran-2-yl]phenyl ester | [Molecular Formula]
C23H24N2O7 | [MOL File]
2242792-25-0.mol | [Molecular Weight]
440.45 |
| Hazard Information | Back Directory | [Uses]
AChE-IN-15 (Compound 3d) is a reversible human acetylcholinesterase (huAChE) (IC50=6.8 μM) and human butyrylcholinesterase (huBChE) (IC50=16.1 μM) inhibitor. AChE-IN-15 shows significant antioxidant potency, AChE-IN-15 can be used for the research of Alzheimer’s disease[1]. | [in vivo]
AChE-IN-15 (compound 3d) (5-20 mg/kg; 14 days; Kunming mice) can reverse cognitive deficit. | Animal Model: | Kunming mice[1] | | Dosage: | 5, 10 and 20 mg/kg | | Administration: | for 14 days | | Result: | Reversed cognitive deficit induced by scopolamine. |
| [References]
[1] Zhipei Sang, et al. Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease. Eur J Med Chem. 2020 Feb 1;187:111958. DOI:10.1016/j.ejmech.2019.111958 |
|
|